Key facts
- This page summarizes Jonathan Piazza's Form 4 filing for Silverback Therapeutics, Inc. (SPRY).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Feb 2022, 16:19.
Jonathan Piazza - 01 Feb 2022 Form 4 Insider Report for Silverback Therapeutics, Inc. (SPRY)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- SPRY
- Reported as of
- 01 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Feb 2022, 16:19:53 UTC
- Next SEC filing
- 04 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeffrey C. Pepe, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Piazza filed Form 4 for Silverback Therapeutics, Inc. (SPRY) on 02 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SPRY
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +11,250
- Change %
- +79%
- Price
- $0.000000
- Shares after
- 25,534
- Date
- 01 Feb 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SPRY
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +67,500
- Change %
- Price
- $0.000000
- Shares after
- 67,500
- Date
- 01 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 67,500
- Exercise price
- $4.85
- Footnotes
- F3
SPRY
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +42,750
- Change %
- Price
- $0.000000
- Shares after
- 42,750
- Date
- 01 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,750
- Exercise price
- $4.85
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
Includes 2,054 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on June 30, 2021 and 326 shares acquired under the ESPP on December 31, 2021.
Footnote F3
The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022.
Footnote F4
25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years.